Trials / Not Yet Recruiting
Not Yet RecruitingNCT07396870
A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dosed Phase II Clinical Study to Evaluate the Efficacy and Safety of LPM787000048 Maleate Extended-Release Tablets (LY03020) in Acutely Psychotic Adult Subjects With Schizophrenia
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Luye Pharma Group Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, fixed-dosed phase II clinical study to evaluate the efficacy and safety of LY03020 in chinese acutely psychotic adult subjects with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY03020 | administered orally |
| DRUG | Placebo | administered orally |
Timeline
- Start date
- 2026-03-31
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2026-02-09
- Last updated
- 2026-02-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07396870. Inclusion in this directory is not an endorsement.